Ongoing projects include:
1) the investigation of the pathophysiologic role of the AP-1 family members of transcription factors JunB and cJun in Multiple Myeloma (Fan et al., Leukemia 2017)
2) the delineation of the pathophysiologic role of Mcl-1 in both Breast Cancer and Multiple Myeloma; as well as the preclinical evaluation of the therapeutic potential of innovative Mcl-1 inhibitors (Bashari et al. Breast Cancer Res 2016); and
(3) the identification of molecular mechanisms contributing to tumor associated bone disease both in Multiple Myeloma and Breast Cancer (Vallet at al., PLoS One 2016).